SEC Form 4 · accession 0001628280-16-021971
Bellerophon Therapeutics, Inc. · BLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jens Luehring
Director · 10% Owner
Period of report
Dec 9, 2016
Accepted (ET)
Dec 12, 2016 · 10:10 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001600132
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 9, 2016 | P | 20,000 | $0.56 | A | 39,860 | D | |
| Common StockF1 | holding | — | — | — | 3,549,804 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares are owned directly by Linde North America, Inc. ("Linde"). Jens Luehring is a director and chief financial officer of Linde. Mr. Luehring disclaims beneficial ownership of all shares held by Linde, except to the extent of his pecuniary interest therein.